Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Abstract

In progressive immunoglobulin (Ig)A nephropathy (IgAN), cyclophosphamide pulse therapy (CyP), high-dose intravenous immunoglobulins (IVIg) and mycophenolic acid (MPA) have been used to stop progressive loss of renal function, but disease progression may occur after the end of the initial treatment. Here, we report the long-term follow-up of patients with progressive IgAN with MPA as maintenance therapy after CyP (CyP-MPA). In a median observation time of 6·2 years, we analysed the slopes of the loss of renal function of 47 patients with biopsy-proven IgAN and treated with CyP. Thirty-one patients with further progression were treated with MPA maintenance for a median time of 5·2 years. Follow-up was compared with symptomatic therapy and IVIg as historically matched control groups. Median loss of renal function was reduced significantly from 0·9 ml/min to 0·1 ml/min per month with CyP (P < 0·05), and with MPA in patients with a relapse from -0·4 ml/min to -0·1 ml/min per month (P < 0·05) until the end of the study. Proteinuria decreased significantly from 1·6 g/l to 1·0 g/l after CyP, and during MPA treatment to 0·6 g/l (P = 0·001 Friedman test). Median renal survival time was in patients with CyP 10·5 years (range = 3·2-17·8), with CyP-MPA 10·7 years (range = 8·3-13·1), with IVIg 4·7 years (range = 2·6-6·6), and in untreated patients 1·2 years (range = 0·8-1·6; log-rank test P < 0·01). In patients with progressive IgAN, our long-term follow-up observation indicates that sequential CyP-MPA therapy maintains renal survival significantly.

• Authors: F M Rasche, F Keller, W G Rasche, S Schiekofer, T Kahn, J Fahnert
• Journal: Clinical and experimental immunology (Clin Exp Immunol) Vol. 183 Issue 2 Pg. 307-16 (Feb 2016) ISSN: 1365-2249 [Electronic] England
• PMID: 26439797 (Publication Type: Journal Article)
• Copyright: © 2015 British Society for Immunology.

Chemical References

• Immunosuppressive Agents
• Cyclophosphamide
• Mycophenolic Acid

Topics

• Adult
• Aged
• Cyclophosphamide (administration & dosage, adverse effects, therapeutic use)
• Disease Progression
• Follow-Up Studies
• Glomerulonephritis, IGA (drug therapy)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Kidney (drug effects, physiology)
• Maintenance Chemotherapy
• Male
• Middle Aged
• Mycophenolic Acid (administration & dosage, adverse effects, therapeutic use)
• Proteinuria (drug therapy)
• Risk Factors